L-asparaginase is a crucial chemotherapeutic agent for the treatment of acute lymphoblastic leukemia. However, hypersensitivity to L-asparaginase is common which limits its usage.
We performed 44 cases premedication and 3 cases of desensitization in 16 patients with hypersensitivity to L-asparaginase.
With premedication, 33 cases completed L-asparaginase injection with no hypersensitivity reaction. 11 cases showed mild hypersensitivity reaction, such as urticaria. Desensitization was performed in 3 cases: 2 cases were successful and in 1 case, medication was switched to Erwiniaasparaginase.
Premedication and desensitization appears to be useful in helping patients receive desired dose of L-asparaginase in pediatric patients with acute lymphoblastic leukemia.